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Pathogenic defects in NO-cGMP signaling drive skeletal
muscle dysfunction in Duchenne muscular dystrophy
(DMD). These defects arise from decreased nNOS and gua-
nylyl cyclase (GC) activity and loss of spatial control of NO
production. Therapeutics such as sildenafil that amplify
NO-cGMP signaling reduce skeletal muscle dysfunction in
DMD patients and mouse models of DMD making GC and
cGMP attractive therapeutic targets. However, GC and
cGMP functions in skeletal muscle are poorly defined hin-
dering therapy development. To remove this barrier, we
investigated the functions of GC in skeletal muscle.
We report that a1b1 soluble GC (sGC) is the primary
cGMP source in skeletal muscle. a1b1 sGC expression
was greater in oxidative muscles suggesting a greater
cGMP synthesis capacity and muscle-specific differences
in sGC function. Interestingly, sGC activity exhibited par-
tial nNOS dependence. Analyses of sGC subcellular locali-
zation revealed a pool of a1b1 at the cis-Golgi complex in
muscle cells. a1b1 and a2b1 sGC localized to the micro-
vasculature. Muscles lacking a functional a1 sGC subunit
(a1b1 sGC deficient) exhibited reduced fatigue resistance
and normal hypertrophic growth. Surprisingly, a1b1 sGC
deficiency had no impact on mitochondrial content sug-
gesting that mitochondrial density may not be as tightly
regulated by cGMP as previously thought. a1b1 sGC defi-
ciency had a modest effect on mitochondrial ATP synth-
esis. Also, loss of a1b1 sGC triggered a type IIA to type
IIX fiber shift. Although this shift was unlikely to signifi-
cantly enhance fatigability, it may impact insulin metabo-
lism because type IIX fiber content positively correlates
with insulin insensitivity. Indeed, a1b1 sGC null mice
exhibited gender-specific defects in whole body insulin
sensitivity consistent with reports of gender-specific effects
of cGMP on metabolism but normal glucose tolerance
indicating compensatory changes in glucose metabolism.
In summary, these findings argue that NO signaling
through sGC plays important roles in muscle fatigue and
fiber type specification and suggest sGC as a target for
mitigating skeletal muscle fatigue in DMD. These data
also suggest that disruption of NO-cGMP signaling may
contribute to the poorly understood metabolic defects in
DMD patients. By showing that reductions in cGMP
synthesis promote muscle fatigue, type IIX content and
insulin resistance, these data suggest new insights as to
how decreases in cGMP may contribute to the develop-
ment of metabolic dysfunction and disease, particularly
over time. Importantly, these results suggest sGC as a
potential target for mitigating insulin resistance.
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